Abstract
Background & Aims
Low hepatitis delta prevalence estimates in the United States are likely biased due to low testing rates. The objectives of this study were to quantify the prevalence of testing and identify factors associated with hepatitis D positive status among chronic hepatitis B patients in the Veterans Health Administration
Methods
We performed a nationwide retrospective study of all veterans who tested positive for HBsAg from October 1999 to December 2013. Hepatitis D antibody testing results were used to stratify patients into 3 groups: HDV-positive, HDV-negative and HDV-not tested. Demographics, comorbidities, additional laboratory data and clinical outcomes were compared across these groups of patients using standard statistical approaches.
Results
Among 25,603 patients with a positive hepatitis B surface antigen, 2,175 (8.5%) were tested for HDV; 73 (3.4%) patients tested positive. Receiving HDV testing was associated with receipt of testing for HBV, HIV, and HCV. Predictors of positive HDV results included substance abuse and cirrhosis. Fitting a predefined high-risk profile (abnormal ALT with suppressed HBV DNA titers) was strongly associated with testing positive for HDV (OR 4.2, 95%CI 1.9–9.3). Most (59%) of HDV-positive patients were HCV co-infected. HDV-positive subjects had higher risks of all-cause mortality. Incidence rates of hepatocellular carcinoma were 2.9 fold higher in HDV-positive relative to HDV-negative individuals (p=0.002). In adjusted analyses, HDV was independently associated with HCC (OR 2.1, 95%CI 1.1–3.9).
Conclusions
Testing rates for hepatitis delta in chronic hepatitis B patients in the United States are inappropriately low. Approaches to increase testing for HDV particularly in high-risk subsets should be explored.
Keywords: Hepatitis D, Hepatitis B, hepatocellular carcinoma, database
INTRODUCTION
Hepatitis Delta virus (HDV) is an incomplete human RNA virus that requires chronic hepatitis B (HBV) infection for replication.1, 2 Super-infection of individuals with chronic HBV with HDV frequently results in chronic delta hepatitis, which has been associated with accelerated fibrosis progression and increased risk of hepatocellular carcinoma (HCC) relative to hepatitis B mono-infection.3, 4 The prevalence of chronic delta hepatitis in the United States is thought to be rising due to increased sexual transmission and increasing prevalence in certain urban injection drug using populations.2, 5 To date, however, no study has examined the prevalence, risk factors, and clinical outcomes in HDV among a national US cohort.
The objectives of this study were to report on the prevalence of HDV testing, HDV co-infection and associated adverse clinical outcomes such as HCC and hepatic decompensation among a national cohort of U.S. Veterans. We additionally examined factors associated with HDV testing, HDV positive status, and adverse clinical outcomes.
METHODS
Data Source
This was a retrospective cohort study from October 1999 to December 31, 2013 using the VA Corporate Data Warehouse (CDW), a national data repository updated with daily demographic information, laboratory results, prescription fills, and claims information (e.g. diagnosis codes) from all outpatient and inpatient encounters from the Veterans Health Administration, which serves 8.76 million US veterans each year at over 1,700 sites. The CDW is a relational database that has been utilized extensively for epidemiology studies in chronic viral hepatitis studies6–8. In a cohort of HBsAg-positive individuals, the following demographic and laboratory data were extracted: age, gender, race/ethnicity, presence and results of anti-HDV antibody (HDVAb), HDV RNA, HBeAg, HBeAb, HBV DNA titers, HBcIgM, HIV antibody (HIVAb), Hepatitis C antibody (HCVAb), alanine aminotransferase (ALT), total bilirubin, and international normalized ratio (INR). We also report the proportion of patients that ever had a positive HCV RNA. The presence of chronic confirmed HBV was defined as having a second positive HBsAg, second positive HBeAg, or positive HBV DNA more than 6 months following the original positive HBsAg result. We pre-defined a high-risk for HDV laboratory profile of suppressed HBV DNA titers (<2,000 IU/mL) and elevated ALT (≥2 x ULN, 62 U/mL) for specific analyses. The number of prescriptions and dates of interferon and oral nucleos(t)ide antivirals was obtained from outpatient pharmacy data. Patients were considered to have received interferon or oral nucleos(t)ides (lamivudine, telbivudine, adefovir, entecavir, or tenofovir) if they filled at least one outpatient prescription. Hepatic decompensation was defined using a previously validated algorithm including International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for ascites, variceal hemorrhage, and spontaneous bacterial peritonitis.9 Cirrhosis was ascertained using ICD-9-CM codes using previously validated methodology.10 Significant alcohol use was defined as having a score of ≥5 on the Alcohol Use Disorders Identification Test (AUDIT-C).11 Drug abuse was identified using ICD-9-CM codes. We classified patients as having had specialty care if they had at least one appointment with a gastroenterology (GI) or infectious disease (ID) specialist within two years of the index HBsAg+ result. Death events were identified using the Vital Status File12 censored as of 12/31/2013.
Statistical Analysis
Descriptive statistics such as means, standard deviations, medians and interquartile ranges were calculated. Medians for continuous variables were compared using the Kruskal-Wallis test and proportions for categorical variables were compared using the chi squared test. Univariate and multivariable logistic regression was used to evaluate factors associated with the outcomes of HDV testing and positive HDV status. For logistic regression models, goodness of fit was evaluated with the Hosmer-Lemeshow goodness of fit test. Incidence rates (cases per 1000 person years) and incidence rate ratios were calculated for the outcomes of hepatocellular carcinoma (HCC), hepatic decompensation, and death. Multivariable Cox proportional hazards models were conducted for the outcome of HCC. For the outcome of HCC, two models were constructed: model 1 included all covariates with a p<0.05 on univariate analyses of association with HCC development; model 2 was a parsimonious model including only covariates found to be statistically significant in multivariable analysis. The proportional hazards assumption was tested using Schoenfeld residuals. All analyses were conducted with Stata 12.1 (StataCorp, College Station, Texas). To account for possible misclassification bias due to low rates of HDV testing, we conducted sensitivity analyses to assess clinical outcomes such as HCC, hepatic decompensation, and death among patients not tested for HDV, but meeting a high risk profile (ALT ≥2 ULN and HBV DNA < 2000 IU/mL).
RESULTS
Characteristics of the HBsAg+ study cohort and HDV testing rates
A total of 25,603 HBsAg+ patients were identified from the VA Corporate Data Warehouse. Of these, 8,159 (32%) of patients were confirmed to have chronic HBV infection with subsequent virologic and serologic testing. However, given the low rates of serologic testing and low prevalence of HDV, analyses were performed among the entire cohort. The patient population was predominantly male and non-Asian (33% African American, 40% white). 2,008 (7.8%) of all HBsAg+ patients were tested for HDV and 73 (3.6%) were HDV seropositive (HDV-positive) (Table 1). The average age of the cohort was 52 (SD=12) and did not vary by testing status. HDV-positive patients were more likely to have documented alcohol abuse and substance abuse than HDV-negative patients. The prevalence of HCV, HIV co-infection and cirrhosis was higher among HDV-positive patients. The majority of HDV-positive patients (64%) did not have HBV DNA testing performed within the VA system, however, among those tested 88% (23 of 26) had HBV DNA <2,000 IU/mL. Peak ALT and total bilirubin were significantly higher in tested individuals (p<0.001). Among the 5,935 patients with available data, 1,468 (25%) met the high-risk HDV profile defined by HBV DNA <2,000 IU/mL and ALT ≥2 ULN; the percentage of patients with the high-risk profile in the HDV positive group was more than twice that of the HDV negative group (62% versus 28%).
Table 1.
Variable, N (%) | Total (N=25,603) | HDV Not Tested (N=23,595) | HDV Negative (N=1,935) | HDV Positive (N=73) | P value* |
---|---|---|---|---|---|
Age (M, SD) | 52 (12) | 52 (12) | 52 (12) | 51 (10) | 0.52 |
Male | 24,140 (94) | 22,202 (94) | 1,867 (96) | 71 (97) | <0.001 |
<0.001 | |||||
Race | |||||
Black | 8,313 (33) | 7,638 (32) | 649 (34) | 26 (36) | |
White | 10,339 (40) | 9,332 (39) | 970 (50) | 37 (51) | |
Asian | 1,149 (4.5) | 1,045 (4.4) | 100 (5.2) | 4 (5.5) | |
Indian/Hawaiian/PI | 484 (1.9) | 449 (1.9) | 34 (1.8) | 1 (1.4) | |
Unknown/Refused | 5,380 (21) | 5,192 (22) | 183 (9.5) | 5 (6.7) | , |
Alcohol abuse | 13,917 (54) | 13,145 (56) | 734 (38) | 38 (52) | <0.001 |
Substance abuse | 5,397 (21) | 4,927 (21) | 434 (22) | 36 (49) | <0.001 |
HCV ab positive | 4,331 (17) | 3,964 (17) | 324 (17) | 43 (59) | <0.001 |
HCV RNA positive | 2,728 (11) | 2501 (11) | 206 (11) | 21 (29) | <0.001 |
HIV co-infection | 1,195 (4.7) | 1,053 (4.5) | 135 (7.0) | 7 (9.6) | <0.001 |
Cirrhosis | 1,937 (7.5) | 1,625 (6.9) | 290 (15) | 22 (30) | <0.001 |
HBV DNA | <0.001 | ||||
<2,000 IU/mL | 3,985 (16) | 3,400 (14) | 562 (29) | 23 (32) | |
2,000–20,000 IU/mL | 512 (2.0) | 425 (1.8) | 87 (4.5) | 0 (0) | |
>20,000 IU/mL | 1,437 (5.6) | 1,104 (4.7) | 330 (17) | 3 (4.1) | |
Not tested | 19,669 (77) | 18,666 (79) | 956 (49) | 47 (64) | |
Peak ALT (median, IQR) (n=16,569) | 49 (29, 105) | 47 (28, 96) | 78 (38, 260) | 84 (44,201) | <0.001 |
High Risk Profile* | 1,468 (25) | 1,181 (24) | 271 (28) | 16 (62) | <0.001 |
Peak Total Bilirubin (median, IQR) (n=16,460) | 0.8 (0.6, 1.2) | 0.8 (0.6, 1.2) | 1.0 (0.7, 1.8) | 1 (0.6, 2.7) | <0.001 |
Peak INR (median, IQR) (n=8,719) | 1.1 (1.0, 1.3) | 1.1 (1.0, 1.3) | 1.1 (1.0, 1.3) | 1.1 (1.0, 1.3) | 0.09 |
Seen by Specialist | 5743 (22) | 4719 (20) | 988(51) | 36(49) | <0.001 |
GI/Hepatology | 3904 (15) | 3134 (13) | 744(38) | 26 (36) | <0.001 |
Infectious Disease | 2172(8.5) | 1832(7.8) | 326(17) | 14(19) | <0.001 |
Abbreviations: M=mean, SD=standard deviation, ALT=alanine aminotransferase, INR=international normalized ratio, IQR=interquartile range
Alcohol abuse/dependence= AUDIT-C score ≥5
Substance abuse/dependence, HIV and cirrhosis identified by ICD-9-CM codes
High risk profile refers to patients with ALT ≥2 ULN and HBV DNA <2,000 IU/mL, (data available for n=5,935)
Factors associated with HDV Testing
In order to address differences between patients who were tested and those who were not tested, we compared these two cohorts of patients (Table 2). We found that age was similar across groups (p=0.49). White (OR 1.2, 95%CI 1.1–1.3)) and male subjects (OR 1.8, 95%CI 1.4–2.3) were more like to be tested. Patients who also underwent testing for HBeAg, HBeAb, HBV DNA, HBcIgM, HCV, and HIV serologies were more likely to be HDV-tested, suggesting that diagnostic work-up for ALT flares, which were more prevalent in the tested group, frequently prompted appropriate HDV testing. Notably, HBeAg and HBeAb testing were associated with the highest odds ratios for HDV testing among the variables studied (12.3 and 8.9, respectively), likely reflecting increased testing for HDV in setting of concern for change in HBV infection phase and disease activity. Not surprisingly, patients with outpatient visits with Gastroenterology or Infectious Disease specialists were more than three times more likely to undergo HDV testing (OR 3.3, 95% CI3.0–3.6). Patients with the high-risk profile for HDV were indeed more likely to be HDV tested (RR 1.3, p<0.001) yet despite this, 1,181 of 1,468 (80%) subjects with the high- risk profile in the cohort were not HDV tested (Table 1). HDV-tested patients were more likely to be exposed to interferon or nucleoside therapy (ORs 3.1 and 2.4, respectively), possibly due to higher rates of active hepatitis in these individuals. By contrast, HCV co-infection and alcohol abuse were associated with reduced HDV testing (OR=0.86, p<0.001 and OR=0.50, p<0.001, respectively) possibly due to attribution of abnormal liver associated enzymes to chronic HCV or alcohol abuse in these individuals. In summary, patients who underwent more comprehensive HBV testing were also more likely to be HDV tested. Together, these data suggest that coordination of testing by specialists with expertise in HBV resulted in higher testing of HDV.
Table 2.
Variable | Unadjusted OR (95% CI) | P value |
---|---|---|
Age (per 1 year increase) | 0.99 (0.99–1.00) | 0.49 |
White | 1.2 (1.1–1.3) | <0.001 |
Male | 1.8 (1.4–2.3) | <0.001 |
HBeAg tested | 12.3 (9.1–12.2) | < 0.001 |
Anti-HBe tested | 8.9 (7.8–10.0) | < 0.001 |
HBV DNA tested | 3.8 ((3.5–4.2) | < 0.001 |
HCV Ab tested | 2.2 (1.9–2.5) | < 0.001 |
HIV tested | 2.6 (2.3–2.8) | < 0.001 |
HBcIgM tested | 2.1 (1.9–2.3) | < 0.001 |
HBcIgM+ | 3.0 (2.6–3.5) | < 0.001 |
HBeAg+ | 1.7 (1.6–1.9) | < 0.001 |
HCV Ab+ | 0.86 (0.76–0.97) | 0.014 |
Alcohol abuse | 0.50 (0.45–0.55) | <0.001 |
Substance abuse | 1.2 (1.0–1.3) | 0.007 |
Cirrhosis | 2.5 (2.2–2.8) | <0.001 |
High risk profile* | 1.3 (1.1–1.5) | 0.002 |
Oral nucleoside therapy | 3.1 (2.9–3.4) | < 0.001 |
Interferon therapy | 2.4 (1.9–3.1) | <0.001 |
Specialty care (GI/ID) | 3.3 (3.0–3.6) | <0.001 |
Gastroenterology/Hepatology | 4.0 (3.7–4.5) | <0.001 |
Infectious Disease | 2.4 (2.1–2.7) | <0.001 |
Abbreviations: OR=odds ratio, CI=confidence interval, HBeAg= hepatitis B e antigen, Anti-HBe (hepatitis B antibody), HBV=hepatitis B virus, HCV=hepatitis C virus
Substance abuse, cirrhosis obtained using ICD-9-CM codes
Alcohol abuse = score of ≥5 on AUDIT-C questionnaire
Specialty care=at least 1 outpatient visit with gastroenterology or infectious disease specialist within 2 years of initial HBV diagnosis
High risk profile refers to patients with ALT ≥2 ULN and HBV DNA <2,000 IU/mL
Factors associated with a positive HDV result
When comparing patients who tested positive versus those who tested negative for HDV among those tested (Table 3), strikingly, HBV/HCV-co-infected individuals were significantly more likely to test positive for HDV (OR 7.1, 95%CI 4.4–11.5), possibly related to common routes of exposure of HCV and HDV. Not unexpectedly, HBcIgM+ and HBeAg+ patients conversely were much less likely to test positive for HDV (OR 0.21, p=0.009 and OR 0.39, p=0.002, respectively) as ALT elevations and higher disease activity in these individuals would be more consistent with hepatitis B mono-infection-related flares. Other factors positively associated with an HDV-positive result included alcohol abuse (OR 1.8, 95%CI 1.1–2.8) and expectedly substance abuse (OR 3.4, 95%CI 2.1–5.4). ICD9-coded cirrhosis was also positively associated with HDV-positivity (OR 2.4, 95%CI 1.5–4.1), likely related to the known more aggressive progression of fibrosis associated with HDV. The predefined high-risk profile (high ALT, low HBV DNA) was strongly associated with testing positive for HDV (OR 4.2, 95% 1.9–9.3). Finally, interferon therapy was associated with HDV-positive results, an association that could reflect initiation of current standard of care therapy, but could also reflect the higher rates of HCV co-infection in HDV-positive individuals.
Table 3.
Variable | Unadjusted (OR, 95% CI) | P value | Adjusted (OR, 95% CI) | P value |
---|---|---|---|---|
HCV Ab+ | 7.1 (4.4–11.5) | <0.001 | 3.2 (1.4–7.6) | 0.007 |
Alcohol abuse | 1.8 (1.1–2.8) | 0.016 | 3.2 (1.4–7.8) | 0.009 |
Cirrhosis | 2.4 (1.5–4.1) | 0.001 | 3.5 (1.4–8.5) | 0.006 |
High risk profile* | 4.2 (1.9–9.3) | <0.001 | 3.2 (1.4–7.5) | 0.007 |
HBcIgM+ | 0.21 (0.07–0.68) | 0.009 | 0.18 (0.02–1.5) | 0.107 |
HBeAg+ | 0.39 (0.21–070) | 0.002 | 0.50 (0.17–1.4) | 0.182 |
Substance abuse | 3.4 (2.1–5.4) | <0.001 | 2.0 (0.83–5.0) | 0.119 |
Interferon therapy | 2.7 (1.2–6.1) | 0.016 | 1.4 (0.27–7.1) | 0.693 |
Abbreviations HBcIgM = hepatitis b core IgM, HCV hepatitis c virus
Substance abuse, cirrhosis obtained using ICD-9-CM codes
Alcohol abuse = score of ≥5 on AUDIT-C questionnaire
High risk profile refers to patients with ALT ≥2 ULN and HBV DNA <2,000 IU/mL
Confirmatory Testing
A minority (n=6, 8.2%) of HDV-positive subjects underwent confirmatory PCR testing. A total of 2% of patients who tested negative for HDV antibody were tested with PCR.
Antiviral therapy
Of the 73 HDV-positive patients, a total of 7 (9.6%) were exposed to interferon-based therapy. Of interferon-treated patients, the median number of month-long fills 7 (IQR: 1–16). A total of 30 (41%) of HDV-positive patients received HBV-directed nucleos(t)ide therapy.
Clinical Outcomes
Incidence rates per 1,000-person years for the outcomes of hepatocellular carcinoma (HCC), hepatic decompensation, and death are presented in Table 4. The overall incidence of HCC was 3.9 per 1,000-person years; 23.0 per 1,000 person-years in HDV-positive individuals and 8.0 per 1,000 person-years in HDV-negative individuals (IRR 2.9, 95% CI 1.5–5.4). The incidences of hepatic decompensation and death was 8.0 and 44.0 cases per 1,000-person years, respectively, rates were numerically higher for HDV-positive patients, approaching statistical significance for both outcomes.
Table 4.
Variable | HDV Not tested (N=23,595) | HDV Negative (N=1,935) | HDV Positive (N=73) | IRR (95% CI) (HDV-positive versus HDV-negative) | P-Value |
---|---|---|---|---|---|
HCC | 3.9 | 8.0 | 23 | 2.9 (1.4–5.4) | 0.002 |
Hepatic Decompensation | 8.0 | 22 | 33 | 1.5 (0.8–2.6) | 0.063 |
Death | 44 | 38 | 52 | 1.4 (0.9–2.1) | 0.059 |
Abbreviations: HCC=hepatocellular carcinoma
Incidence rates reported as cases per 1,000 person-years
We performed multivariable models for the outcome of hepatocellular carcinoma (Table 5). In both models, HDV-positive status, older age, significant alcohol use, and the presence of cirrhosis were independently associated with HCC. Not unexpectedly, increasing age, alcohol abuse, and cirrhosis were also independently associated with HCC. HCV status and nucleos(t)ide therapy was was not significantly associated with the development of HCC.
Table 5.
Variable | Model 1 | Model 2 | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
HDV positive | 1.9 | 1.1–3.7 | 0.044 | 2.1 | 1.1–3.9 | 0.025 |
Age (per 1 year increase) | 1.06 | 1.04–1.08 | <0.001 | 1.05 | 1.03–1.08 | <0.001 |
Significant alcohol use | 2.7 | 1.8–4.0 | <0.001 | 2.5 | 1.7–3.7 | <0.001 |
Cirrhosis | 4.8 | 3.2–7.2 | <0.001 | 5.2 | 3.5–7.8 | <0.001 |
HCV positive | 1.2 | 0.72–1.9 | 0.523 | --- | --- | --- |
Nucleos(t)ide therapy | 1.4 | 0.94–2.2 | 0.093 | --- | --- | --- |
Adjusted IRR adjusted for black race, alcohol abuse, gender, age, HCV and HIV status
DISCUSSION
This is the first nationwide study in the U.S. examining testing rates for hepatitis D (HDV) and outcomes. Testing for HDV infection occurred in fewer than 8% of all HBsAg+ patients and in only 19% of patients with hepatitis not attributable to active hepatitis B replication. These low testing rates contrast significantly with testing rates internationally13 and suggest a lack of awareness regarding importance of HDV testing in the United States. While practice within the Veterans Affairs medical system may not reflect all United States-based health systems, and certain academic centers may test more frequently2, the authors suspect that the testing rates identified are similar to if not greater than national rates due to frequent affiliation of large urban VA hospitals with neighboring academic centers. Prompt referral to a gastroenterologist/hepatologist or infectious disease specialist was strongly associated with HDV testing. Outpatient visits with gastroenterology/hepatology were more strongly associated with testing than visits with infectious disease specialists. However, this finding should be interpreted with caution as we are unaware of the indications for the outpatient visits and some patients saw both specialists. We hypothesize that low testing rates reflect relative inexperience with HDV, inadequate education of providers regarding high risk groups, infrequent referral rates to appropriate specialists, and poor access to HDV testing modalities.1 Further studies are needed to confirm these hypotheses.
As expected, testing was more common in individuals with elevated ALT levels and patients likely being evaluated for hepatitis flares with concomitant HBcIgM and HBeAg testing. However, patients pre-defined by a high-risk serologic profile of suppressed HBV DNA and elevated ALT were rarely tested (~20% of cases), though among those tested with that profile, greater than half of patients were HDV positive. Small racial differences in testing rates were identified, but these differences are of unclear significance. The 3.4% seropositive prevalence rate of HDVAb in HBsAg-positive U.S. veterans remains relatively low compared to rates seen in endemic regions such as the Mediterranean basis (overall 14.8%14, up to 45.5% in eastern Turkey 15, 16, 44% in Tunisia17), south Asia (17% in Iran18, 16.6% in Pakistan19, 8.6% in Saudi Arabia20), Amazon Basin21 and Mongolia (56–66%)22 and is similar to rates seen in western Europe.13, 23–25 Importantly, as testing rates are quite low, it is difficult to draw conclusions about actual HDV prevalence in the US. Further studies with improved testing for high risk populations will need to be performed to characterize prevalence. In a recent study from Northern California, a relatively high frequency of HDV-positive individuals were of Asian descent 2. In our cohort, only four Asian-Americans tested positive for HDV; this may reflect the low prevalence of Asian veterans within the VHA. These patients did not have co-existent HCV, HIV, or substance abuse, perhaps implying that Asian descent was a risk factor for HDV infection rather than IV drug use however, conclusions are difficult to draw from this limited sample size. The majority of the veterans in our cohort who tested positive for HDV served in the military during the Vietnam war era but exact service locations are unavailable, limiting inferences about the geography of HDV exposures in the cohort.
Outcomes of HDV-positive individuals were markedly poorer relative to HDV-negative individuals with nearly three-fold higher rates of HCC. Even after adjusting for chronic hepatitis C, cirrhosis and alcohol use, which could increase either the prevalence or detection of liver cancer, HDV remained an independent predictor of HCC with a strong trend toward association with hepatic decompensation. Further, overall unadjusted survival was lower in HDV-positive veterans highlighting the importance of testing and potential treatment.
The American Association for the Study of Liver Diseases most recent hepatitis B guidelines from 2009 recommend testing for hepatitis D in patients with a history of injection drug use or from countries with high HDV seroprevalence.26 The recommendation to limit testing to individuals with history of injection drug use could be ineffective at identifying prevalent cases due to significant underreporting of remote illicit drug use in the past.27 Furthermore, focusing testing on just patients from the Mediterranean basin and the developing world may be inappropriate in the United States due to significant prevalence (8% in one study from California)2 in non-Mediterranean Caucasian and Asian populations. Overall adherence to testing recommended by the AASLD HBV guidelines has been shown to be poor28, 29 and thus our finding of low HDV testing rates even among high-risk subgroups in the U.S. is not unexpected.
Strikingly, and confirming the findings of Gish et al.2 and Kucirka et al.5 our data show that HCV co-infection was present in the majority of HDV-positive patients suggesting a dominant role for high-risk behaviors such as injection drug use and high-risk sexual contact for transmission of HDV. We also found that the high risk profile (indicating high ALT and low HBV DNA) was strongly associated with increased likelihood of HDV-positive status, however, only minimally associated with increased likelihood of HDV testing. We would propose that future iterations of U.S.-based HBV guidelines more strongly emphasize the need to test for HDV in patients at high-risk including those co-infected (HIV/HBV, HCV/HBV, HIV/HCV/HBV) and patients with active hepatitis despite suppressed HBV DNA titers, particularly those that are HBeAg-negative.
Among the 73 HDV-positive individuals in our study, only 7 received current standard of care therapy with long-term interferon-alpha; 5 of those patients had HCV, leaving only 2 treated solely for HDV. In this cohort, few HDV-positive individuals received confirmatory HDV RNA testing by PCR, this most likely due to poor availability testing in the U.S. during this time-frame. When done in other series, confirmation of HDV RNA by PCR has ranged widely from 16–81% in HDVAb+ patients.15, 30–32 To date, the lack of highly effective, non-toxic therapy33–37 for chronic HDV and lack of convenient testing services likely strongly contributed to the observed low testing and treatment rates. The recent clinical development of Lonafarnib, a farnesyl transferase inhibitor, which appears effective and safe in early clinical trials,38 and other potential therapeutic approaches such as entry HBV inhibitors39 may alter testing and treatment recommendations. It will be critical to improve access to validated and standardized HDV diagnostic tests to accompany HDV drug development in order to appropriately identify treatment candidates and monitor response.
Due to low testing rates for HDV, there is certainly some degree of misclassification bias, specifically that undiagnosed HDV-positive individuals might alter outcome rates in the HDV-not tested group. This could have two possible effects. First, due to less morbid illness in undiagnosed HDV+ individuals that event rates in diagnosed HDV-positive individuals are overestimated (i.e. the Will Rogers Effect). Second, contamination of events from undiagnosed HDV-positive individuals in the HDV-not tested group could falsely minimize real differences in adverse outcomes associated with HDV-positivity. Supporting the latter possibility, risks of HCC, decompensation and death in HDV-not tested individuals who met criteria for the high risk profile , which we found was strongly associated with HDV-positivity, were significantly higher than risks in individuals who did not meet the profile (Supplemental Table 1). Thus, event rates and differences in risk associated with HDV-positivity is most likely underestimated due to underdiagnosis of HDV infection in the cohort.
Several additional limitations of this work must be acknowledged. As a retrospective study, attribution of causation to the associations we identified is limited. Fewer than half of the study cohort met standard criteria for confirmed chronic HBV infection (HBsAg or other marker of ongoing infection 6 months after initial testing). While we were unable to ascertain the exact proportion of patients with acute HBV, the relatively low median ALT (49 IU/ml; 75th percentile 105 IU/ml; 90th percentile 329 IU/ml) and low rates of HBcIgM+ suggest that the vast majority of the patients were indeed chronically infected. As with most VA-based studies, the predominant male gender and other features of the veteran population may limit generalizability. We did not have access to non-VA health records to account for non-VA testing and treatment. Data on substance abuse were administratively coded and subject to recall bias. Information on potential high-risk sex behaviors was also not available.
CONCLUSION
In a large cohort of U.S. veterans with chronic hepatitis B, testing rates for co-infection with hepatitis D were low. Among those tested, the prevalence was 3.4%. Testing appeared to be associated with evaluations for hepatitis flares and most often coordinated by gastroenterology or infectious disease specialists. HDV most commonly seen associated with HBV/HCV co-infection and epidemiologically linked to substance abuse disorders. HDV co-infection was associated with a higher likelihood of cirrhosis, decompensation, and most dramatically with increased hepatocellular carcinoma risk. Most HDV co-infected individuals did not receive effective antiviral therapy. Overall, our findings suggest that the need for updated national guidelines with specific recommendations for screening, treatment and follow-up among patients infected with chronic hepatitis B and hepatitis D are critically needed.
Supplementary Material
Acknowledgments
The authors would like to acknowledge Dr. Theo Heller for his support and direction with regards to the subject matter.
Grant Support: No specific funding source for this project. Dr. Kushner is supported by a training grant NIH T32 (T32-DK007740-18)
Abbreviations
- HDV
hepatitis D
- HDV Ab
hepatitis D antibody
- CDW
VA corporate data warehouse
- HBV
Hepatitis B
- HCV
Hepatitis C
- HBcIgM
Hepatitis B core IgM antibody
- HBeAg
Hepatitis B e antigen
- HBeAb
Hepatitis B e antibody
- HIV
Human immunodeficiency virus
- ALT
Alanine aminotransferase
- INR
International normalized ratio
- AFP
Alpha-fetoprotein
- HCC
hepatocellular carcinoma
Footnotes
Conflict of Interest: None of the authors have conflict of interest to disclose relevant to this work.
Author Contributions:
Tatyana Kushner and David Kaplan worked on the study concept and design of the study in identifying relevant data, collecting the data, and analysis and interpretation of the data. Tatyana Kushner prepared the initial draft of the manuscript. David Kaplan and Marina Serper provided critical revisions of all aspects of the manuscript, from format to intellectual content. Tatyana Kushner, Marina Serper, and David Kaplan performed statistical analyses.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- 1.Noureddin M, Gish R. Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep. 2014;16:365. doi: 10.1007/s11894-013-0365-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gish RG, Yi DH, Kane S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013;28:1521–5. doi: 10.1111/jgh.12217. [DOI] [PubMed] [Google Scholar]
- 3.Fattovich G, Boscaro S, Noventa F, et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis. 1987;155:931–5. doi: 10.1093/infdis/155.5.931. [DOI] [PubMed] [Google Scholar]
- 4.Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep) Gut. 2000;46:420–6. doi: 10.1136/gut.46.3.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202:845–52. doi: 10.1086/655808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Backus LI, Belperio PS, Loomis TP, et al. Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care. Am J Public Health. 2014;104(Suppl 4):S555–61. doi: 10.2105/AJPH.2014.302090. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Butt AA, Fultz SL, Kwoh CK, et al. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology. 2004;40:115–9. doi: 10.1002/hep.20289. [DOI] [PubMed] [Google Scholar]
- 8.Husain N, Blais P, Kramer J, et al. Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014;40:949–54. doi: 10.1111/apt.12923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lo Re V, 3rd, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf. 2011;20:689–99. doi: 10.1002/pds.2148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Goldberg D, Lewis J, Halpern S, et al. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf. 2012;21:765–769. doi: 10.1002/pds.3290. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158:1789–95. doi: 10.1001/archinte.158.16.1789. [DOI] [PubMed] [Google Scholar]
- 12.Sohn MW, Arnold N, Maynard C, et al. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2. doi: 10.1186/1478-7954-4-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59:949–56. doi: 10.1016/j.jhep.2013.07.005. [DOI] [PubMed] [Google Scholar]
- 14.Amini N, Alavian SM, Kabir A, et al. Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis. Hepat Mon. 2013;13:e8210. doi: 10.5812/hepatmon.8210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Mese S, Nergiz S, Tekes S, et al. Seroprevalence of serum HBsAg positivity and hepatitis delta virus infection among blood donors in Southeastern Turkey. Clin Ter. 2014;165:95–8. doi: 10.7471/CT.2014.1683. [DOI] [PubMed] [Google Scholar]
- 16.Bahcecioglu IH, Aygun C, Gozel N, et al. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. J Viral Hepat. 2011;18:518–24. doi: 10.1111/j.1365-2893.2010.01329.x. [DOI] [PubMed] [Google Scholar]
- 17.Triki H, Said N, Ben Salah A, et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg. 1997;91:11–4. doi: 10.1016/s0035-9203(97)90374-6. [DOI] [PubMed] [Google Scholar]
- 18.Bakhshipour A, Mashhadi M, Mohammadi M, et al. Seroprevalence and risk factors of hepatitis delta virus in chronic hepatitis B virus infection in Zahedan. Acta Med Iran. 2013;51:260–4. [PubMed] [Google Scholar]
- 19.Mumtaz K, Hamid SS, Adil S, et al. Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. J Gastroenterol Hepatol. 2005;20:1503–7. doi: 10.1111/j.1440-1746.2005.03857.x. [DOI] [PubMed] [Google Scholar]
- 20.Al-Traif I, Ali A, Dafalla M, et al. Prevalence of hepatitis delta antibody among HBsAG carriers in Saudi Arabia. Ann Saudi Med. 2004;24:343–4. doi: 10.5144/0256-4947.2004.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Braga WS, da Castilho MC, Borges FG, et al. Hepatitis D virus infection in the Western Brazilian Amazon - far from a vanishing disease. Rev Soc Bras Med Trop. 2012;45:691–5. doi: 10.1590/s0037-86822012000600007. [DOI] [PubMed] [Google Scholar]
- 22.Tsatsralt-Od B, Takahashi M, Nishizawa T, et al. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol. 2005;77:491–9. doi: 10.1002/jmv.20482. [DOI] [PubMed] [Google Scholar]
- 23.Ho E, Deltenre P, Nkuize M, et al. Coinfection of hepatitis B and hepatitis delta virus in Belgium: a multicenter BASL study. Prospective epidemiology and comparison with HBV mono-infection. J Med Virol. 2013;85:1513–7. doi: 10.1002/jmv.23653. [DOI] [PubMed] [Google Scholar]
- 24.William Tong CY, Asher R, Toby M, et al. A re-assessment of the epidemiology and patient characteristics of hepatitis D virus infection in inner city London. J Infect. 2013;66:521–7. doi: 10.1016/j.jinf.2013.02.006. [DOI] [PubMed] [Google Scholar]
- 25.Sagnelli E, Sagnelli C, Pisaturo M, et al. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014;20:7635–43. doi: 10.3748/wjg.v20.i24.7635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2. doi: 10.1002/hep.23190. [DOI] [PubMed] [Google Scholar]
- 27.Magura S, Kang SY. Validity of self-reported drug use in high risk populations: a meta-analytical review. Subst Use Misuse. 1996;31:1131–53. doi: 10.3109/10826089609063969. [DOI] [PubMed] [Google Scholar]
- 28.Serper MCG, Forde KA, Kaplan DE. Care Quality and Outcomes among U.S. Veterans with Hepatitis B: A National Cohort Study. Under Review. 2014 [Google Scholar]
- 29.Wu Y, Johnson KB, Roccaro G, et al. Poor adherence to AASLD guidelines for chronic hepatitis B Management and treatment in a large academic medical center. Am J Gastroenterol. 2014;109:867–75. doi: 10.1038/ajg.2014.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Zaidi G, Idrees M, Malik FA, et al. Prevalence of hepatitis delta virus infection among hepatitis B virus surface antigen positive patients circulating in the largest province of Pakistan. Virol J. 2010;7:283. doi: 10.1186/1743-422X-7-283. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Ramia S, El-Zaatari M, Sharara AI, et al. Current prevalence of hepatitis delta virus (HDV) infection and the range of HDV genotypes in Lebanon. Epidemiol Infect. 2007;135:959–62. doi: 10.1017/S0950268806007643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Altuglu I, Ozacar T, Sertoz RY, et al. Hepatitis delta virus (HDV) genotypes in patients with chronic hepatitis: molecular epidemiology of HDV in Turkey. Int J Infect Dis. 2007;11:58–62. doi: 10.1016/j.ijid.2005.10.012. [DOI] [PubMed] [Google Scholar]
- 33.Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330:88–94. doi: 10.1056/NEJM199401133300202. [DOI] [PubMed] [Google Scholar]
- 34.Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713–20. doi: 10.1002/hep.21296. [DOI] [PubMed] [Google Scholar]
- 35.Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–35. doi: 10.1002/hep.21325. [DOI] [PubMed] [Google Scholar]
- 36.Heidrich B, Yurdaydin C, Kabacam G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60:87–97. doi: 10.1002/hep.27102. [DOI] [PubMed] [Google Scholar]
- 37.Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–31. doi: 10.1056/NEJMoa0912696. [DOI] [PubMed] [Google Scholar]
- 38.Koh C, Haynes-Williams V, Hoofnagle JH, et al. Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans. The Liver Meeting 2014: Annual Meeting of the American Association for the Study of Liver Diseases; 2014; p. Abstract 1860. [Google Scholar]
- 39.Volz T, Allweiss L, Ben MM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58:861–7. doi: 10.1016/j.jhep.2012.12.008. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.